XML 28 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1
Prepaid and Other Current Assets
 12 Months Ended
Dec. 31, 2024
Prepaid Expense and Other Assets, Current [Abstract]  
Prepaid and Other Current Assets

5. Prepaid and Other Current Assets

Prepaid assets and other current assets consisted of the following as of December 31, 2024, and 2023 (in thousands):

 

 

 

December 31,

 

 

 

2024

 

 

2023

 

Down payments for inventory

 

$

1,080

 

 

$

16,296

 

Prepaid research and development

 

 

7,780

 

 

 

13,931

 

Other prepaid assets

 

 

9,508

 

 

 

8,593

 

Total prepaid assets

 

$

18,368

 

 

$

38,820

 

 

 

 

December 31,

 

 

 

2024

 

 

2023

 

Royalties receivable

 

$

4,525

 

 

$

3,054

 

Receivable from collaboration agreement (1)

 

 

2,272

 

 

 

15,000

 

Deposits and other current assets

 

 

4,847

 

 

 

4,354

 

Total other current assets

 

$

11,644

 

 

$

22,408

 
(1)
In January 2024 the Company waived the remaining reimbursement payment of $15.0 million in connection with the decision to discontinue the cold agglutinin disease (“CAD”) program. As the reimbursement was related to development costs under the Sobi collaboration agreement, this amount was recorded to research and development expense in the consolidated statements of operations for the period ended December 31, 2024.